ARQ761 + PARP Inhibitor in Refractory Solid Tumors

Sponsor
University of Texas Southwestern Medical Center
Study ID
NCT03575078
Phase
PHASE1
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ARQ761, Olaparib — DRUG
    ARQ761: weekly infusion. Olaparib Dose 1 D-7 administered orally twice daily

Study Details

Open Label, dose escalation in a 3+3 study design to establish the RP2D of the combination of ARQ761 and a PARP inhibitor, Olaparib

Key Dates

Start date
Jun 25, 2018
Status verified
Sep 2019
Primary completion
May 15, 2019
Completion
May 15, 2019

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Maximum tolerated dose of ARQ761 in combination with Olaparib.
    ARQ761: weekly infusion. Olaparib Dose 1 D-7 administered orally twice daily

Primary Outcome Measure

The maximum tolerated dose of ARQ761 in combination with Olaparib. [ Time Frame: Day 1-28 ]

Related Studies